Methotrexate

Infants who have been exposed to tumor necrosis factor inhibitors in utero should receive the rotavirus vaccine in the first 6 months of life, according to new recommendations from the American College of Rheumatology.

The June 24 Supreme Court decision to overturn Roe vs. Wade continues to reverberate across all of health care, including rheumatology, dermatology and cancer treatment — and in this instance all three at once.

Prediction models for rheumatoid arthritis outcomes, including infection and stroke, demonstrated strong performance and may be viable as a study tool for clinical use, according to data published in Seminars in Arthritis and Rheumatism.

Although there are plenty of drugs to treat psoriatic arthritis, and plenty of studies about those drugs individually, there are fewer trials examining strategies to treat patients who fail to respond to methotrexate in the first line.

Federal law prohibits pharmacies from refusing to fill prescriptions that may end a pregnancy to patients who are able to become pregnant, according to a newly released HHS guidance.

The FDA has approved the supplemental biologics license application for pegloticase, expanding the drug’s label to include co-administration with methotrexate in patients with uncontrolled gout, according to a press release.

CHICAGO — For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated.

In the wake of the Supreme Court’s decision overturning Roe v. Wade, rheumatologists and rheumatology associations are voicing concern over what the loss of federal abortion protections could mean for patients.

The 2022 EULAR recommendations for the management of rheumatoid arthritis are largely similar to the 2019 updates, with one point of emphasis being the importance of rapid glucocorticoid reduction and discontinuation.

DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.